Graftys
Graftys is a France-based medical device company founded in 2005 that develops injectable calcium phosphate bone cements and graft substitutes for orthopedic and bone-grafting procedures, serving hospitals, orthopedic clinics, and medical device distributors.
- Company typePrivate
- Founded2005
- HeadquartersAix-en-provence, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Graftys firmographics
Firmographics- Name
- Graftys
- Website
- https://graftys.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Graftys is a France-based medical device company founded in 2005 that develops injectable calcium phosphate bone cements and graft substitutes for orthopedic and bone-grafting procedures, serving hospitals, orthopedic clinics, and medical device distributors.
- Ownership category
- akta.pro rank
Graftys industry classification
Industry- Product category
- Orthopedic Biomaterials
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where Graftys is headquartered
LocationHeadquarters
- HQ city
- Aix-en-provence
- HQ country
- France
- HQ region
- Europe
Markets served
Graftys business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Biomaterial products: Revenue generated from the sale of injectable biomaterial products for bone grafting applications. The company is in a development phase with upcoming product launches planned for 2023 and 2024.
Go-to-market motion1 record
Graftys product offering
Product offeringCore offering
Graftys develops and manufactures injectable biomaterials—specifically calcium phosphate bone cements and bone graft substitutes—for use in bone grafting and orthopedic surgical procedures. Its products are designed to enable minimally invasive bone regeneration procedures and are sold to hospitals, orthopedic clinics, and medical device distributors.
Differentiator
Problem solved
Functional benefit
Products and services
- Calcium phosphate bone cements Injectable calcium phosphate bone cements used in bone grafting and orthopedic procedures to support bone regeneration; sold to hospitals, orthopedic clinics, and medical device distributors.
- Bone graft substitutes Injectable biomaterial bone graft substitutes designed to provide a minimally invasive alternative to traditional bone grafting, addressing limitations of autografts and donor site morbidity; intended for orthopedic and bone regeneration applications.
Companies that use Graftys
Customer profileSegments1 record
Ideal customer profiles1 record
Graftys technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Graftys partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Biologics4LifecoreGraftys acquired Biologics4Life in 2021 as a strategic move to enhance both sales capabilities and innovation capacity. This acquisition provided the company with additional resources to support its development of injectable biomaterials and upcoming product launches.
Scale indicators2 records
Graftys competitors and assessment
Company assessmentDirect peers
- BoneSupport: Swedish orthobiologics company developing injectable bone graft substitutes (CERAMENT platform) for trauma and orthopedic applications. Closely comparable to Graftys in product format (injectable), indication focus, and minimally invasive bone regeneration strategy.
- Biomatlante: France-based developer of synthetic bone substitutes and calcium phosphate-based biomaterials. Direct geographic and technology overlap with Graftys in the calcium phosphate bone graft substitute category.
- Cerapedics: US-based company commercializing peptide-enhanced bone graft substitutes (i-FACTOR) for spinal fusion and orthopedic indications. Directly comparable in bone graft substitute product category and target surgical procedures.
- Curasan: German specialist in bone regeneration and dental biomaterials, offering synthetic bone graft substitutes and membranes. Comparable in product portfolio breadth across bone regeneration, including dental and orthopedic end-uses.
- NovaBone Products: US-based manufacturer of bioactive synthetic bone graft substitutes (calcium phosphosilicate-based). Direct competitor in the synthetic bone graft substitute space with overlapping dental and orthopedic indications.
- Geistlich Pharma: Swiss-headquartered leader in dental bone regeneration and matrix products (Bio-Oss, Bio-Gide). Comparable as a biomaterials specialist serving bone regeneration procedures, though more established and dental-focused.
- Xtant Medical: US orthobiologics company focused on bone graft substitutes and spinal fixation-adjacent products. Comparable as a pure-play orthobiologics specialist of similar scale competing in the same bone graft substitute end-market.
Broad incumbents
- Medtronic (Spine & Biologics): Global medical device leader whose Spine division includes flagship bone graft substitutes such as INFUSE (rhBMP-2). Comparable as the dominant incumbent in the bone graft substitute market Graftys is targeting, with vastly larger sales infrastructure.
- Stryker: Orthopedic and surgical giant with a substantial orthobiologics portfolio (acquired Wright Medical, including bone graft substitutes). Competes broadly in the same end-procedural markets where Graftys' products are used.
- DePuy Synthes (Johnson & Johnson): Major orthopedic and trauma franchise offering synthetic and biologic bone graft solutions as part of its broader implant portfolio. Competes in the same trauma and reconstructive surgery channels as Graftys' bone graft substitutes.
Market position
Customer concentration
Graftys financial estimates
Financial estimateRevenue estimate
Valuation estimate
Graftys leadership team
Management profileNumber of profiles
Profiles2 records
Graftys funding detail
Funding detailFunding overview
Funding rounds5 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Graftys M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Graftys
What does Graftys do?
Graftys develops and manufactures injectable biomaterials—specifically calcium phosphate bone cements and bone graft substitutes—for use in bone grafting and orthopedic surgical procedures. Its products are designed to enable minimally invasive bone regeneration procedures and are sold to hospitals, orthopedic clinics, and medical device distributors.
When was Graftys founded?
Graftys was founded in 2005. It employs 11 to 50 people.
Where is Graftys based?
Graftys is headquartered in Aix-en-provence, France, in the Europe region.
How does Graftys make money?
One revenue line is on record: biomaterial products.
Who are Graftys's main competitors?
Direct peers on record are BoneSupport, Biomatlante, Cerapedics, Curasan, NovaBone Products, Geistlich Pharma and Xtant Medical. Broad incumbents are Medtronic (Spine & Biologics), Stryker and DePuy Synthes (Johnson & Johnson).
Does Graftys have an API?
No public API is recorded for Graftys.
What industry is Graftys in?
Graftys's product category is Orthopedic Biomaterials. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.